MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

03/10/2014 by Arezu Sarvestani

SinuSys CEO Thomas Schreck and CMO Dr. Jerome Hester tell how they hope to replace sinus surgery with a simple, in-office procedure and how a doctor and his patient formed a company together.

Breathing easier with SinuSys | MassDevice Q&A

SinuSys executives Thomas Schreck and Dr. Jerome Hester had a very different relationship just 3 years ago. Schreck, a serial entrepreneur now on his 3rd venture, was Hester's patient up until a fateful lunch meeting in Menlo Park, Calif., that led to the...

02/12/2014 by Brian Johnson

Tom Roberts, CEO of San Antonio, Texas-based startup Invictus Medical discusses the company's approach to preventing the cranial deformation plagiocephaly, also known as flattening of the skull, that affects up to 30% of newborns.

Preventing plagiocephaly: A conversation with Invictus Medical's Tom Roberts

For Tom Roberts, good healthcare starts with prevention.

It's a mantra the CEO of San Antonio, Texas-based startup Invictus Medical holds close to his heart.

In 2010, interrupting a 25-year medical device career that had taken him to Boehringer Manheim, Roche Diagnostics and Kinetic Concepts Inc., Roberts took a leave of...

01/27/2014 by Arezu Sarvestani

Philips Healthcare clinical informatics CEO Michael Mancuso tells how he envisions medtech companies coming together to eliminate preventable hospital injuries and deaths.

A problem for all of us: Philips Healthcare on joining the Patient Safety Movement

Philips Healthcare (NYSE:...

01/20/2014 by Arezu Sarvestani

Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.

Managing renal denervation expectations in the aftermath of Symplicity HTN-3

Medtronic (NYSE:...

12/05/2013 by Arezu Sarvestani

Neurosurgeon Dr. Philip Starr tells about Medtronic's new Activa PC+S brain monitoring, recording and stimulating implant and its potential for treating neurological and psychiatric disease.

Medtronic, the 'brain pacemaker' and the future of neurological disease treatment

Deep-brain stimulation is about to get a major upgrade and medtech titan Medtronic (NYSE:...

11/25/2013 by Brian Johnson

ResMed CEO Mick Farrell tells about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

The story behind ResMed's (NYSE:RMD) meteoric rise from Baxter spinout to $1.5 billion medical device Goliath is no snore.

Or maybe it is. After all, stopping snoring has paid off pretty nicely for the San Diego-based sleep apnea device company, which has a more than 40% share in the growing market for...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp